KRAS and non-small cell lung carcinoma: In NSCLC, the co-occurrence of KRAS and Serine/Threonine Kinase 11 (STK11) mutations is associated with the diverse phenotypic and heterogeneous oncogenic subtypes in the so-called “KRAS KL” NSCLC subgroup [11].